BRPI0510691A - marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento - Google Patents

marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento

Info

Publication number
BRPI0510691A
BRPI0510691A BRPI0510691-5A BRPI0510691A BRPI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A
Authority
BR
Brazil
Prior art keywords
methods
treatment
present
haplotype
determine response
Prior art date
Application number
BRPI0510691-5A
Other languages
English (en)
Inventor
Beena Koshy
Bradley J Dain
Madan Kamur Anant
Ping Zhan
Original Assignee
Genaissance Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals filed Critical Genaissance Pharmaceuticals
Publication of BRPI0510691A publication Critical patent/BRPI0510691A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MARCADORES DE HAPLóTIPOS E MéTODOS DE USO DOS MESMOS PARA DETERMINAR RESPOSTA AO TRATAMENTO. A presente invenção relaciona-se a métodos para diagnóstico ou previsão da capacidade de resposta ao tratamento, como Alefacept, por determinação da presença de um nucleotídeo em um ou mais sítios polimórficos em um marcador de haplótipo. A presente invenção identifica múltiplos haplótipos que estão associados à resposta a Alefacept. Os marcadores de haplótipo identificados pela presente invenção e métodos da invenção podem ser particularmente úteis para o diagnóstico ou previsão da suscetibilidade a doenças da pele, como Psoríase.
BRPI0510691-5A 2004-05-04 2005-05-04 marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento BRPI0510691A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56837104P 2004-05-04 2004-05-04
PCT/US2005/015531 WO2005112568A2 (en) 2004-05-04 2005-05-04 Haplotype markers and methods of using the same to determine response to treatment

Publications (1)

Publication Number Publication Date
BRPI0510691A true BRPI0510691A (pt) 2007-12-26

Family

ID=35428732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510691-5A BRPI0510691A (pt) 2004-05-04 2005-05-04 marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento

Country Status (9)

Country Link
US (1) US20080020383A1 (pt)
EP (1) EP1747291A2 (pt)
KR (1) KR20070011558A (pt)
CN (1) CN1997756A (pt)
BR (1) BRPI0510691A (pt)
CA (1) CA2565804A1 (pt)
IL (1) IL178970A0 (pt)
MX (1) MXPA06012744A (pt)
WO (1) WO2005112568A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149612A1 (en) * 2008-07-29 2010-02-03 Merck Serono SA Genetic markers of response to efalizumab
GB2467162A (en) 2009-01-26 2010-07-28 Sharp Kk Fabrication of nitride nanoparticles
GB2467161A (en) 2009-01-26 2010-07-28 Sharp Kk Nitride nanoparticles
MX378797B (es) * 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
KR20170023776A (ko) 2014-02-26 2017-03-06 루마 세러퓨틱스 인코포레이티드 자외선 광선 치료 장치들 및 방법들
KR20180134856A (ko) 2016-02-09 2018-12-19 루마 세러퓨틱스 인코포레이티드 광선요법에 의해 건선을 치료하기 위한 방법, 조성물 및 장치
CN114085873A (zh) * 2021-11-16 2022-02-25 珠海中科先进技术研究院有限公司 一种癌细胞状态辨识基因电路组及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (ja) * 1985-11-26 1995-07-12 アスモ株式会社 ダイカスト鋳造金型への離型剤塗布方法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
RU2166512C2 (ru) * 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
GEP20063828B (en) * 2001-02-01 2006-05-10 Biogen Inc Methods for Treating or Preventing Skin Disorders Using CD2-Binding Agents
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders

Also Published As

Publication number Publication date
WO2005112568A2 (en) 2005-12-01
WO2005112568A3 (en) 2006-05-11
CN1997756A (zh) 2007-07-11
CA2565804A1 (en) 2005-12-01
IL178970A0 (en) 2007-03-08
EP1747291A2 (en) 2007-01-31
KR20070011558A (ko) 2007-01-24
US20080020383A1 (en) 2008-01-24
MXPA06012744A (es) 2007-02-19

Similar Documents

Publication Publication Date Title
Ikeda et al. HLA class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
Chen et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome
EA200970578A1 (ru) Генетические маркеры для предотвращения риска аритмии сердца
James et al. Complex epigenetic regulation of engrailed-2 (EN-2) homeobox gene in the autism cerebellum
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
BRPI0507442A (pt) métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
BRPI0908425B8 (pt) métodos para predizer uma predisposição para desenvolver alcoolismo, e para predizer uma resposta para o tratamento contra alcoolismo, e, uso de um antagonista do receptor de serotonina 5-ht3
BRPI1013546A2 (pt) usos de um inibidor da timidilato sintase e de uma terapia anticâncer
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
BRPI0712225A8 (pt) métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r
WO2012018535A3 (en) Wellness panel
EP2637020A3 (en) Predictive markers for ovarian cancer
BRPI0718322A2 (pt) Métodos para diagnosticar uma suscetibilidade para câncer em um indivíduo humano, para identificar um marcador para o uso na avaliação da suscetibilidade para câncer, para genotipar uma amostra de ácido nucléico, para avaliar um inidivíduo quanto a probabilidade de resposta a um agente terapêutico, para predizer o prognóstico e para monitorar o progresso de um tratamento de um indivíduo, kit para avaliar a suscetibilidade para câncer em um indivíduo, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para câncer em um indivíduo.
BR0308161A (pt) métodos para a detecção de distúrbios genéticos
JP2016536012A5 (pt)
BR112013006528A2 (pt) fosfolipidoma de câncer
ATE531820T1 (de) Gesundheitszustandstest
BR112013013457A2 (pt) métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições
Takemoto et al. Hair mi R‐29a levels are decreased in patients with scleroderma
WO2010054195A3 (en) Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
Khan et al. PCR/RFLP-based analysis of genetically distinct Plasmodium vivax population of Pvmsp-3α and Pvmsp-3β genes in Pakistan
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.